{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T19:36:14Z","timestamp":1770147374763,"version":"3.49.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.contraception.2009.08.004","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T13:07:04Z","timestamp":1254402424000},"page":"1-7","source":"Crossref","is-referenced-by-count":46,"title":["Mifepristone: ten years later"],"prefix":"10.1016","volume":"81","author":[{"given":"Eric A.","family":"Schaff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2009.08.004_bib1","unstructured":"http:\/\/www.who.int\/reproductivehealth\/topics\/unsafe_abortion\/hrpwork\/en\/index.html [accessed June 18, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib2","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(06)69778-X","article-title":"Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries","volume":"368","author":"Singh","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.08.004_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.AOG.0000116260.81570.60","article-title":"Risk factors for legal induced abortion-related mortality in the United States","volume":"103","author":"Bartlett","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/4000608","article-title":"Abortion in the United States: incidence and access to services, 2005","volume":"40","author":"Jones","year":"2008","journal-title":"Perspect Sexual Repro Health"},{"key":"10.1016\/j.contraception.2009.08.004_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2307\/3097714","article-title":"Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden","volume":"34","author":"Jones","year":"2002","journal-title":"Perspect Sexual Repro Health"},{"key":"10.1016\/j.contraception.2009.08.004_bib6","unstructured":"WHO. Essential Medicines, WHO Model List 20 (14th edition, revised March 2005) at http:\/\/www.who.int\/medicines\/publications\/08_ENGLISH_indexFINAL_EML15.pdf [accessed May 17, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0015-0282(16)59465-5","article-title":"Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane","volume":"48","author":"Birgerson","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2009.08.004_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0010-7824(96)00080-7","article-title":"Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy","volume":"53","author":"Creinin","year":"1996","journal-title":"Contraception"},{"issue":"5 Pt 1","key":"10.1016\/j.contraception.2009.08.004_bib9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0029-7844(02)01944-0","article-title":"Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol","volume":"99","author":"Wiebe","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.272.15.1190","article-title":"Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial","volume":"272","author":"Creinin","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2009.08.004_bib11","first-page":"198","article-title":"Methotrexate and misoprostol for early abortion","volume":"28","author":"Schaff","year":"1996","journal-title":"Fam Med"},{"key":"10.1016\/j.contraception.2009.08.004_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"Spitz","year":"1998","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2009.08.004_bib13","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/humrep\/13.10.2962","article-title":"An effective regimen for early medical abortion: a report of 2000 consecutive cases","volume":"13","author":"Ashok","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2009.08.004_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0029-7844(97)00111-7","article-title":"Absorption kinetics of misoprostol with oral or vaginal administration","volume":"90","author":"Zieman","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2005.05.017","article-title":"Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period","volume":"72","author":"Middleton","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib16","unstructured":"http:\/\/www.acog.org\/publications\/patient_education\/bp043.cfm [accessed June 18, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib17","unstructured":"http:\/\/www.guideline.gov\/summary\/summary.aspx?ss=15&doc_id=12522&nbr=6446 [accessed June 18, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib18","unstructured":"http:\/\/www.rcog.org.uk\/womens-health\/clinical-guidance\/about-abortion-care-what-you-need-know [accessed June 18, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib19","unstructured":"http:\/\/whqlibdoc.who.int\/publications\/2006\/9241594845_eng.pdf [accessed June 18, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib20","unstructured":"http:\/\/codes.ohio.gov\/orc\/2919.123 [accessed June 14, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib21","unstructured":"http:\/\/en.wikipedia.org\/wiki\/Off-label_use [accessed September 20, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib22","unstructured":"http:\/\/www.earlyoptionpill.com\/section\/health_professionals\/providing_mifeprex and http:\/\/www.earlyoptionpill.com\/userfiles\/file\/MedicationGuide071905.pdf [accessed September 20, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/00016349209006230","article-title":"Women's evaluation of three early abortion methods","volume":"71","author":"Holmgren","year":"1992","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2009.08.004_bib24","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1001\/jama.284.15.1948","article-title":"Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial","volume":"284","author":"Schaff","year":"2000","journal-title":"JAMA"},{"issue":"5 Pt 1","key":"10.1016\/j.contraception.2009.08.004_bib25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.AOG.0000124271.23499.84","article-title":"A randomized comparison of misoprostol 6\u20138 hours versus 24 hours after mifepristone for abortion","volume":"103","author":"Creinin","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.AOG.0000258298.35143.d2","article-title":"Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial","volume":"109","author":"Creinin","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol","volume":"332","author":"el-Refaey","year":"1995","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2009.08.004_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.contraception.2006.08.001","article-title":"Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated","volume":"75","author":"Clark","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9378(97)70511-8","article-title":"Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone\u2013misoprostol versus surgical abortion","volume":"176","author":"Winikoff","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0140-6736(00)04563-3","article-title":"Can women in less-developed countries use a simplified medical abortion regimen","volume":"357","author":"Elul","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.08.004_bib31","unstructured":"Wu S. Medical abortion in China. J Am Med Womens Assoc 2004;55(3 Suppl):197--179, 204."},{"key":"10.1016\/j.contraception.2009.08.004_bib32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/13625180701536300","article-title":"Medical abortion in the first trimester: the use of serum hCG and endometrial thickness as markers of completeness","volume":"12","author":"Parashar","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.08.004_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0002-9378(79)90383-1","article-title":"Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion","volume":"135","author":"Marrs","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.contraception.2007.01.021","article-title":"Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited","volume":"75","author":"Godfrey","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.contraception.2006.11.011","article-title":"Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research","volume":"75","author":"Clark","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.2000.tb13273.x","article-title":"Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial","volume":"107","author":"WHO Task Force on Post-ovulatory Methods of Fertility Regulation","year":"2000","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.contraception.2005.12.011","article-title":"Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion","volume":"73","author":"Kapp","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejogrb.2003.12.024","article-title":"Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion","volume":"116","author":"Liao","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biology"},{"key":"10.1016\/j.contraception.2009.08.004_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1471-0528.2001.00171.x","article-title":"Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial","volume":"108","author":"World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation","year":"2001","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2009.08.004_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0029-7844(97)00419-5","article-title":"Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy","volume":"90","author":"Ho","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejogrb.2005.02.019","article-title":"Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone","volume":"123","author":"Arvidsson","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2009.08.004_bib42","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/humrep\/deg475","article-title":"A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation","volume":"18","author":"Tang","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2009.08.004_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.contraception.2005.03.011","article-title":"Safety of mifepristone abortions in clinical use","volume":"72","author":"Henderson","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1783\/147118908784734846","article-title":"Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa","volume":"34","author":"Kawonga","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"3 Suppl","key":"10.1016\/j.contraception.2009.08.004_bib45","first-page":"191","article-title":"Early medical abortion in India: three studies and their implications for abortion services","volume":"55","author":"Coyaji","year":"2000","journal-title":"J Am Med Wom Assoc"},{"key":"10.1016\/j.contraception.2009.08.004_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0010-7824(02)00295-0","article-title":"Users' perspectives on medical abortion in Finland","volume":"65","author":"Honkanen","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2307\/2136257","article-title":"Acceptabilty of medical abortion in early pregnancy","volume":"27","author":"Winikoff","year":"1995","journal-title":"Fam Plann Perspect"},{"key":"10.1016\/j.contraception.2009.08.004_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0010-7824(02)00492-4","article-title":"The learning curve is rapid in medical termination of pregnancy\u2013first-year results from the Helsinki area","volume":"67","author":"Suhonen","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(99)00115-8","article-title":"The efficacy of medical abortion: a meta-analysis","volume":"61","author":"Kahn","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.contraception.2008.06.002","article-title":"Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac","volume":"78","author":"Reeves","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib51","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1471-0528.2000.tb13272.x","article-title":"Epidemiological assessment of misoprostol teratogenicity","volume":"107","author":"Orioli","year":"2000","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.contraception.2009.08.004_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1345\/aph.1G481a","article-title":"Analysis of severe adverse events related to the use of mifepristone as an abortifacient","volume":"40","author":"Gary","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.contraception.2009.08.004_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0029-7844(01)01375-8","article-title":"Curettage after mifepristone-induced abortion: frequency, timing, and indications","volume":"98","author":"Allen","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib54","first-page":"724","article-title":"Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol \u2014 United States and Canada, 2001\u20132005","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR"},{"key":"10.1016\/j.contraception.2009.08.004_bib55","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMoa051620","article-title":"Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion","volume":"353","author":"Fischer","year":"2005","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2009.08.004_bib56","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/01.AOG.0000287291.19230.ba","article-title":"Toxic shock associated with Clostridium sordellii and Clostidium perfringens after medical and spontaneous abortion","volume":"110","author":"Cohen","year":"2007","journal-title":"Obst Gynecol"},{"issue":"5 Pt 2","key":"10.1016\/j.contraception.2009.08.004_bib57","first-page":"884","article-title":"Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis","volume":"87","author":"Sawaya","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib58","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMc055539","article-title":"Deaths from Clostridium sordellii after medical abortion","volume":"354","author":"Baulieu","year":"2006","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2009.08.004_bib59","unstructured":"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm111341.htm [accessed September 20, 2009]."},{"key":"10.1016\/j.contraception.2009.08.004_bib60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa0809146","article-title":"Rates of serious infection after changes in regimens for medical abortion","volume":"361","author":"Fjerstad","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.contraception.2009.08.004_bib61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3500603","article-title":"Abortion incidence and services in the United States in 2000","volume":"35","author":"Finer","year":"2003","journal-title":"Perspect Sexual Reprod Health"},{"key":"10.1016\/j.contraception.2009.08.004_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.gyobfe.2005.02.021","article-title":"The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients","volume":"33","author":"Faucher","year":"2005","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.contraception.2009.08.004_bib63","unstructured":"Gemperli MP, Stewart FH, Phillips KA, Sakowski J, Van Bebber S, Bergthold L. A qualitative study of insurers' coverage for mifepristone-induced abortion. Managed Care Interface 2005;18:26--30, 32."},{"key":"10.1016\/j.contraception.2009.08.004_bib64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1363\/3709205","article-title":"Advanced practice clinicians' interest in providing medical abortion: results of a California survey","volume":"37","author":"Hwang","year":"2005","journal-title":"Perspect Sex Reprod Health"},{"key":"10.1016\/j.contraception.2009.08.004_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.contraception.2007.04.007","article-title":"Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion?","volume":"76","author":"Leeman","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.004_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.whi.2004.08.011","article-title":"Willing and able? Provision of medication for abortion by future internists","volume":"15","author":"Schwarz","year":"2005","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.contraception.2009.08.004_bib67","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1471-0528.2008.01787.x","article-title":"Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services","volume":"115","author":"Gomperts","year":"2008","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.contraception.2009.08.004_bib68","first-page":"CD001324","article-title":"Interventions for emergency contraception","author":"Cheng","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2009.08.004_bib69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/01.AOG.0000259319.18958.76","article-title":"Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion","volume":"109","author":"Bracken","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib70","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1471-0528.2005.00638.x","article-title":"A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation","volume":"118","author":"Hamoda","year":"2005","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2009.08.004_bib71","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/humrep\/dei037","article-title":"A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation","volume":"20","author":"Hamoda","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2009.08.004_bib72","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1046\/j.1471-0528.2002.01462.x","article-title":"A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy","volume":"109","author":"Bartley","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2009.08.004_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/01443610310001620332","article-title":"Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective?","volume":"24","author":"Coughlin","year":"2004","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1471-0528.2002.01238.x","article-title":"Medical management of late intrauterine death using a combination of mifepristone and misoprostol","volume":"109","author":"Wagaarachchi","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2009.08.004_bib75","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1471-0528.1991.tb13482.x","article-title":"Pretreatment of the primigravid uterine cervix with mifepristone 30 h prior to termination of pregnancy: a double-blind study","volume":"98","author":"Cohn","year":"1991","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib76","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/oxfordjournals.humrep.a135933","article-title":"Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial","volume":"10","author":"World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2009.08.004_bib77","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","article-title":"Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression","volume":"60","author":"DeBattista","year":"2006","journal-title":"Biol Psych"},{"key":"10.1016\/j.contraception.2009.08.004_bib78","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing's syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.contraception.2009.08.004_bib79","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.antiviral.2006.06.008","article-title":"Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR)","volume":"72","author":"Schafer","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.contraception.2009.08.004_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J Minimally Invasive Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib81","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.fertnstert.2005.05.056","article-title":"Management of patients receiving long-term treatment with mifepristone","volume":"84","author":"Spitz","year":"2005","journal-title":"Fertil Steril"},{"issue":"2 Pt 2","key":"10.1016\/j.contraception.2009.08.004_bib82","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.AOG.0000223228.23289.0f","article-title":"Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma","volume":"109","author":"Koivisto-Korander","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.004_bib83","unstructured":"Bygdeman M, Danielsson KG, Marions L. Medical termination of early pregnancy: the Swedish experience. J Am Med Womens Assoc 2000;55(3 Suppl):195--6, 204."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782409003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782409003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:59:38Z","timestamp":1558569578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782409003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0010782409003825"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2009.08.004","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}